Vivici
- Type
- Food & Ingredient Manufacturer
- Location
- Delft, Netherlands
- Industries
- Alternative proteins, Food ingredients & products, Consumer health & consumer effects, New food processing techniques
- Domains
- Ingredients, Proteins, Processed food products, Dairy products, Dietary supplements, Feed
- Technologies
- Precision fermentation, Fermentation, Biotechnology & sustainable inputs, Extraction, Processing
About Vivici
Vivici is a Dutch B2B ingredients company founded in 2023 that develops animal-free dairy proteins using precision fermentation. It serves food and beverage brands, especially in active nutrition and health-and-wellness applications, with ingredients designed to deliver protein functionality, nutrition, and a better fit with modern consumer preferences.
The company positions itself as a commercial and technical partner rather than just a supplier. Across its website, Vivici emphasizes premium protein performance, great sensorials, reliable supply, and support for brands that want to launch innovative products more quickly and sustainably.
Core Values
- Customer centricity: Vivici says it starts with the customer’s challenges and ambitions, then designs solutions intended to exceed expectations and create real-world impact.
- Can-do mindset: The company describes itself as positive, resilient, and curious, focusing on solutions, learning quickly, and taking smart risks to keep moving forward.
- Collaborative spirit: Vivici emphasizes open feedback, shared knowledge, empathy, and teamwork as a competitive advantage in working with partners and colleagues.
- Relentless ambition: It presents itself as goal-driven and disciplined, aiming to turn precision fermentation into a commercial reality and push beyond what is currently possible.
Unique Aspects
- Precision-fermentation dairy proteins: Vivici’s core differentiator is that it produces dairy proteins without animals, using precision fermentation rather than conventional dairy extraction.
- Two-ingredient platform: The company has built the Vivitein™ platform around both beta-lactoglobulin and lactoferrin, giving it a broader functional protein portfolio than a single-ingredient launch.
- Commercial and technical depth: Vivici repeatedly highlights its combination of scientific, technical, and commercial expertise, including application support and market validation for customers.
- External validation and funding: Vivici secured €32.5 million in Series A funding in 2025, led by APG on behalf of ABP and Invest-NL, and later received EUR 12.5 million from the European Innovation Council in 2026.
- Strategic partnerships for scale-up: The company has publicly partnered with Ginkgo Bioworks for strain development and, according to known news, scaled production to 75,000 liters at Bio Base Europe Pilot Plant in Belgium, with commercial manufacture planned with Liberation Bioindustries in Indiana.